Select Pharmaceuticals PortfolioFPHAX
Type
Mutual fund
Peer group
Global equity
Net assets
$1.5B
Expense ratio
0.67%
1-year return
+27.7%
3 years, a year
+21.8%
5 years, a year
+14.1%
Holdings
60
What it aims to do.
Pharmaceuticals Portfolio seeks capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY ELI LILLY and CO | 25.18% |
| GSK Gsk Plc | 10.07% |
| JNJ JOHNSON and JOHNSON | 7.53% |
| Ucb Sa | 5.00% |
| Roche Holding Ag | 4.93% |
| Astrazeneca Plc | 4.93% |
| GILD Gilead Sciences Inc | 4.64% |
| MRK MERCK and CO INC | 4.59% |
| ELAN Elanco Animal Health Inc | 4.42% |
| Fidelity Revere Street Trust | 4.26% |
More on FPHAX.
- FPHAX overview
- FPHAX holdings
- FPHAX risk
- FPHAX costs
- FPHAX money in and out
- FPHAX share classes
- Compare FPHAX with other funds
Returns after fees, from the fund's SEC filings up to Feb 2026. Past returns are not a promise. Not financial advice.